Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARTmeso and CART19 in Pancreatic Cancer
NCT03497819Phase 1Unknown
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Oct 2017
- Primary completion
- Oct 2019
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CART-meso cells and ARI-0001 in pancreatic cancer (PC), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: Percentage of Adverse Events (AEs) >= grade 3 at 3 months. Status: unknown.
02
Drugs
CART-meso cellsARI-0001
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03497819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03497819.